PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
I will review the fundamental limiting issues in in-vivo optical imaging and discuss the proposal made by the IN2SIGHT consortium to overcome them and its impact. IN2SIGHT will foster a breakthrough in in-vivo optical imaging that will renovate the biocompatibility tests (ISO10993 EU norm) required for the development of biomaterials for clinical use. These tests are economical and ethical unsustainable for small-medium industries and for the society.
The IN2SIGHT approach stands on a micro-structured chip that will recast our thinking of deep tissue in-vivo imaging.
I discuss how this proposal will allow unique quantification of the immune reaction to biomaterials, thus reducing time and costs for testing with a potential huge impact on public health systems and our society. The project sees the collaboration of seven partners from five countries and will exploit from the beginning inter-sectorial approaches in an interdisciplinary environment.
Giuseppe Chirico
"IN2SIGHT: an in vivo bioengineered chip for new validation protocols of biomaterials", Proc. SPIE 11786, Optical Methods for Inspection, Characterization, and Imaging of Biomaterials V, 1178608 (24 June 2021); https://doi.org/10.1117/12.2595057
ACCESS THE FULL ARTICLE
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Giuseppe Chirico, "IN2SIGHT: an in vivo bioengineered chip for new validation protocols of biomaterials," Proc. SPIE 11786, Optical Methods for Inspection, Characterization, and Imaging of Biomaterials V, 1178608 (24 June 2021); https://doi.org/10.1117/12.2595057